Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of both patent-protected and off patent medicines.
We produce medicines to treat a broad range of acute and chronic diseases. These include respiratory disease, skin conditions and viral infections.
While our global pharmaceuticals portfolio covers seven areas – respiratory, immune-inflammation, infectious disease, cardiovascular, metabolic, dermatology and rare diseases – we are particularly known in Australia for our respiratory medicines.
Since the invention of our first asthma treatment in the 1960s, we have invested more in respiratory research than any other company worldwide and we remain committed to providing new treatment options for respiratory patients.
Our pharmaceutical manufacturing plant in Melbourne’s outer-east is GSK’s largest manufacturing facility in the Southern Hemisphere. Our Boronia site is also our fourth-largest sterile facility housing a state-of-the-art Blow-Fill-Seal production line that runs 24 hours a day. Blow-Fill-Seal uses innovative technology for advanced antiseptic liquid medicines. Products manufactured in this facility are exported to over 30 markets around the world.
Our Boronia capabilities focus on high volume products and Blow-Fill-Seal manufacturing, which is highly skilled and specialised work. However, we will have less need of these capabilities in future years as we develop GSK’s innovative pipeline of specialised medicines in respiratory, oncology, immunology and vaccine. In October 2020, we announced that following a review, we will be closing our Boronia manufacturing site at the end of 2022.
Our HIV medicines are managed through ViiV Healthcare, a joint venture between GSK, Pfizer and Shionogi. ViiV Healthcare Australia has been involved in supporting research through investigator initiated clinical studies and operates its sales and marketing function from GSK’s Abbotsford office in Melbourne.